MwanzoBLUE • NASDAQ
add
bluebird bio Inc
$ 7.59
Baada ya Saa za Kazi:(0.40%)-0.030
$ 7.56
Imefungwa: 27 Jan, 16:22:30 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 7.80
Bei za siku
$ 7.40 - $ 8.24
Bei za mwaka
$ 5.80 - $ 38.40
Thamani ya kampuni katika soko
73.79M USD
Wastani wa hisa zilizouzwa
elfu 365.14
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 10.61M | -14.36% |
Matumizi ya uendeshaji wa biashara | 62.94M | -36.60% |
Mapato halisi | -60.81M | 30.29% |
Kiwango cha faida halisi | -573.01 | 18.60% |
Mapato kwa kila hisa | -6.20 | 53.03% |
EBITDA | -48.76M | 44.96% |
Asilimia ya kodi ya mapato | 0.10% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 70.65M | -59.46% |
Jumla ya mali | 465.06M | -24.21% |
Jumla ya dhima | 470.84M | 20.40% |
Jumla ya hisa | -5.79M | — |
hisa zilizosalia | 9.72M | — |
Uwiano wa bei na thamani | -13.00 | — |
Faida inayotokana na mali | -31.73% | — |
Faida inayotokana mtaji | -39.19% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -60.81M | 30.29% |
Pesa kutokana na shughuli | -68.93M | -37.72% |
Pesa kutokana na uwekezaji | elfu 466.00 | -99.25% |
Pesa kutokana na ufadhili | -6.10M | 48.42% |
Mabadiliko halisi ya pesa taslimu | -74.57M | -38,339.49% |
Mtiririko huru wa pesa | -48.44M | 22.76% |
Kuhusu
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.
The company's only - in the European Union - approved drug is betibeglogene autotemcel, which treats transfusion-dependent beta thalassemia, a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.
The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
16 Apr 1992
Makao Makuu
Tovuti
Wafanyakazi
282
